Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals and the Lewy Body Dementia Association have announced a partnership to produce an educational adaptation of the film Robin's Wish. This new version, titled SPARK - Robin Williams and his Battle with Lewy Body Dementia, aims to increase awareness and educate healthcare professionals about Lewy body dementia (LBD), which affects 1.4 million people in the U.S. The film will be available in late October for academic institutions to aid in outreach and education on LBD symptoms and management.